Mn Services Vermogensbeheer B.V. Purchases 1,300 Shares of McKesson Co. (NYSE:MCK)

Mn Services Vermogensbeheer B.V. raised its stake in shares of McKesson Co. (NYSE:MCK) by 2.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 52,600 shares of the company’s stock after acquiring an additional 1,300 shares during the quarter. Mn Services Vermogensbeheer B.V.’s holdings in McKesson were worth $29,977,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in MCK. Allegiance Financial Group Advisory Services LLC bought a new stake in McKesson during the 4th quarter worth approximately $215,000. Whipplewood Advisors LLC acquired a new stake in shares of McKesson during the fourth quarter valued at about $249,000. Advisor OS LLC acquired a new position in McKesson in the fourth quarter valued at approximately $302,000. Lake Street Advisors Group LLC increased its holdings in shares of McKesson by 5.0% during the fourth quarter. Lake Street Advisors Group LLC now owns 2,092 shares of the company’s stock valued at $1,194,000 after acquiring an additional 99 shares in the last quarter. Finally, Longbow Finance SA grew its holdings in McKesson by 5.0% during the fourth quarter. Longbow Finance SA now owns 9,877 shares of the company’s stock worth $5,629,000 after buying an additional 468 shares in the last quarter. 85.07% of the stock is owned by institutional investors.

McKesson Stock Down 0.4 %

NYSE:MCK opened at $624.53 on Thursday. McKesson Co. has a 52-week low of $464.42 and a 52-week high of $637.51. The company has a market capitalization of $78.27 billion, a PE ratio of 28.60, a price-to-earnings-growth ratio of 1.29 and a beta of 0.52. The stock has a fifty day simple moving average of $592.07 and a 200-day simple moving average of $563.06.

McKesson (NYSE:MCK) last released its quarterly earnings data on Wednesday, February 5th. The company reported $8.03 earnings per share for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%. As a group, equities analysts anticipate that McKesson Co. will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 1st. Investors of record on Monday, March 3rd will be issued a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 0.45%. The ex-dividend date of this dividend is Monday, March 3rd. McKesson’s dividend payout ratio is currently 13.00%.

Insider Buying and Selling

In other news, EVP Leann B. Smith sold 579 shares of the business’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $572.79, for a total value of $331,645.41. Following the sale, the executive vice president now owns 864 shares in the company, valued at approximately $494,890.56. The trade was a 40.12 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Brian S. Tyler sold 8,961 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $600.66, for a total transaction of $5,382,514.26. Following the transaction, the chief executive officer now owns 69,625 shares in the company, valued at $41,820,952.50. The trade was a 11.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 19,268 shares of company stock worth $11,536,378. 0.11% of the stock is owned by company insiders.

Analyst Ratings Changes

MCK has been the topic of a number of recent research reports. StockNews.com cut McKesson from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th. Wells Fargo & Company increased their target price on McKesson from $535.00 to $641.00 and gave the company an “equal weight” rating in a research note on Friday, December 13th. Robert W. Baird upgraded McKesson from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $531.00 to $688.00 in a research report on Thursday, November 7th. Evercore ISI upped their price objective on McKesson from $650.00 to $675.00 and gave the stock an “outperform” rating in a report on Thursday, February 6th. Finally, Morgan Stanley lifted their target price on McKesson from $612.00 to $642.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 17th. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, McKesson has an average rating of “Moderate Buy” and a consensus target price of $645.79.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.